Probiotics in Depression Management: Efficacy, Mechanisms and Future Directions

Depression affects approximately 280 million people worldwide, representing a significant public health burden. It is characterized by persistent sadness, anhedonia, fatigue, sleep disturbances, cognitive dysfunction, and in severe cases, suicidal ideation. The pathophysiology is often attributed t...

Full description

Saved in:
Bibliographic Details
Main Author: Learn-Han Lee
Format: Article
Language:English
Published: HH Publisher 2025-01-01
Series:Progress in Microbes and Molecular Biology
Online Access:https://journals.hh-publisher.com/index.php/pmmb/article/view/1103
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832540317570564096
author Learn-Han Lee
author_facet Learn-Han Lee
author_sort Learn-Han Lee
collection DOAJ
description Depression affects approximately 280 million people worldwide, representing a significant public health burden. It is characterized by persistent sadness, anhedonia, fatigue, sleep disturbances, cognitive dysfunction, and in severe cases, suicidal ideation. The pathophysiology is often attributed to neurotransmitter imbalances, hypothalamic-pituitary-adrenal (HPA) axis dysfunction, and inflammation. Recently, the gut-brain axis has garnered attention for its role in mood regulation, suggesting that probiotic supplementation may influence depressive symptoms through gut microbiome modulation. Therefore, this review examines recent findings and research gaps regarding the efficacy of probiotics in managing clinically diagnosed depression. Emerging research demonstrates that daily probiotic supplementation from 3×109 CFU to 9×1011 CFU for four to eight weeks in combination with antidepressants is effective in improving depressive symptoms. Effective formulations commonly included Bifidobacteria, Lactobacilli, Lactococcus lactis, and Streptococcus thermophilus. Nevertheless, significant gaps remain, particularly concerning the mechanistic pathways, comparative effectiveness, and impact across different demographics of the probiotics. Furthermore, the long-term effects of probiotic use with antidepressants, their role in reducing antidepressant side effects, and combined effects with psychotherapy are largely understudied. Addressing these gaps through standardized methodologies will enhance evaluations of probiotic strains to optimize microbiome-based treatment regimens, and ultimately improve mental health outcomes in depression management.  Graphical abstract. Summary of research gaps and future directions to determine the efficacy of probiotics in diagnosed depression.
format Article
id doaj-art-4f249c484b064bddbe8094ec7bf0cd84
institution Kabale University
issn 2637-1049
language English
publishDate 2025-01-01
publisher HH Publisher
record_format Article
series Progress in Microbes and Molecular Biology
spelling doaj-art-4f249c484b064bddbe8094ec7bf0cd842025-02-05T05:10:23ZengHH PublisherProgress in Microbes and Molecular Biology2637-10492025-01-0181Probiotics in Depression Management: Efficacy, Mechanisms and Future DirectionsLearn-Han Lee Depression affects approximately 280 million people worldwide, representing a significant public health burden. It is characterized by persistent sadness, anhedonia, fatigue, sleep disturbances, cognitive dysfunction, and in severe cases, suicidal ideation. The pathophysiology is often attributed to neurotransmitter imbalances, hypothalamic-pituitary-adrenal (HPA) axis dysfunction, and inflammation. Recently, the gut-brain axis has garnered attention for its role in mood regulation, suggesting that probiotic supplementation may influence depressive symptoms through gut microbiome modulation. Therefore, this review examines recent findings and research gaps regarding the efficacy of probiotics in managing clinically diagnosed depression. Emerging research demonstrates that daily probiotic supplementation from 3×109 CFU to 9×1011 CFU for four to eight weeks in combination with antidepressants is effective in improving depressive symptoms. Effective formulations commonly included Bifidobacteria, Lactobacilli, Lactococcus lactis, and Streptococcus thermophilus. Nevertheless, significant gaps remain, particularly concerning the mechanistic pathways, comparative effectiveness, and impact across different demographics of the probiotics. Furthermore, the long-term effects of probiotic use with antidepressants, their role in reducing antidepressant side effects, and combined effects with psychotherapy are largely understudied. Addressing these gaps through standardized methodologies will enhance evaluations of probiotic strains to optimize microbiome-based treatment regimens, and ultimately improve mental health outcomes in depression management.  Graphical abstract. Summary of research gaps and future directions to determine the efficacy of probiotics in diagnosed depression. https://journals.hh-publisher.com/index.php/pmmb/article/view/1103
spellingShingle Learn-Han Lee
Probiotics in Depression Management: Efficacy, Mechanisms and Future Directions
Progress in Microbes and Molecular Biology
title Probiotics in Depression Management: Efficacy, Mechanisms and Future Directions
title_full Probiotics in Depression Management: Efficacy, Mechanisms and Future Directions
title_fullStr Probiotics in Depression Management: Efficacy, Mechanisms and Future Directions
title_full_unstemmed Probiotics in Depression Management: Efficacy, Mechanisms and Future Directions
title_short Probiotics in Depression Management: Efficacy, Mechanisms and Future Directions
title_sort probiotics in depression management efficacy mechanisms and future directions
url https://journals.hh-publisher.com/index.php/pmmb/article/view/1103
work_keys_str_mv AT learnhanlee probioticsindepressionmanagementefficacymechanismsandfuturedirections